Metastatik tiroid kanserinde sistemik tedavi etkinliğinin retrospektif olarak değerlendirilmesi

Amaç: Tiroid kanserleri, endokrin kanserleri içerisinde en

Anahtar Kelimeler:

Tiroid, Kanser, Sorafenib

A retrospective analysis of efficacy of systemic therapy in metastatic thyroid cancer

Objective: Thyroid cancer is the most common type of endocrine

Keywords:

Thyroid, Cancer, Sorafenib,

PDF

___

1. Shah JP. Thyroid carcinoma: Epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol 2015; 13(4 Suppl 4): 3-6.
2. Brown RL, De Souza JA, Cohen EE. Thyroid cancer: Burden of illness and management of disease. J Cancer 2011;2:193- 199. doi: https://doi.org/10.1530/ERC-16-0372.
3. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 (suppl 1): vii110–9. doi.org/10.1093/annonc/mds230.
4. Barut F. Tiroid kanserlerinin patolojisi. Turkiye Klinikleri J Med Oncol-Special Topics 2017;10:10-2.
5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 ;19:1167-214. doi: 10.1089/ thy.2009.0110.
6. Albero A, Lopéz JE, Torres A, et al. Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endoc Relat Cancer 2016;23:R71-84. doi: 10.1530/ERC-15-0194.
7. Kormaz T, Er Ö. Tiroid kanserlerinde tirozin kinaz inhibitör tedavisi, kemoterapi ve gelecekteki olası tedaviler. Turkiye Klinikleri J Med Oncol-Special Topics 2017;10:50-5.
8. Baran A., Yılmaz M. Tiroid kanserlerinde kemoterapi ve hedefe yönelik tedaviler. Türkiye Kanserle Savaş Vakfı Kanser Gündemi Tiroid Kanseri 2015;3/3:62-4.
9. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Eng Med J 1974;290:193-7. doi:10.1056 /NEJM 197.401.242900404
10. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60. doi: 10.1002/1097- 0142(19851101)56:9<2155.
11. Matuszczyk A, Petersenn S, Voigt W, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2010;42:61-4. doi: 10.1055/s-0029.123.8294.
12. Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9. doi: 10.1200/JCO.2008.16.3279.
13. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84. doi: 10.1200/JCO.2008.18.2717.
14. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28. doi: 10.1016/S0140- 6736(14)60421-9.
15. Schlumberger M, Tahara M, Wirth LJ et al. Lenvatinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015;372:621-30. doi: 10.1056/NEJMoa1406470